logo

Alnylam Pharmaceuticals Inc. (ALNY)



Trade ALNY now with
  Date
  Headline
11/19/2021 7:06:44 AM Alnylam Plans To Initiate Phase 3 Study In Patients With Stargardt Disease In Late 2022
11/8/2021 7:06:17 AM Alnylam Initiates KARDIA-2 Phase 2 Study Of Zilebesiran In Patients With Hypertension
10/18/2021 8:04:16 AM Alnylam Receives Positive Recommendation From CADTH For Use Of GIVLAARI For Treatment Of Acute Hepatic Porphyria
10/13/2021 7:33:43 AM Alnylam Announces Launch Of Alnylam Challengers
9/28/2021 8:03:54 AM Alnylam Pharma Says ONPATTRO Now Reimbursed In Canada For Hereditary Transthyretin-Mediated Amyloidosis
9/13/2021 7:04:40 AM Alnylam Submits MAA To EMA For Vutrisiran For Hereditary ATTR Amyloidosis With Polyneuropathy
9/7/2021 7:08:33 AM Alnylam Presents Addl 9-Month Data From HELIOS-A Phase 3 Study Of Vutrisiran At EU-ATTR Amyloidosis Meeting
8/9/2021 7:04:14 AM Alnylam Completes Enrollment In HELIOS-B Phase 3 Study Of Vutrisiran
8/3/2021 8:07:22 AM Alnylam Pharmaceuticals Inc. (ALNY) Has Raised Its FY21 Revenue Estimate To $640 - $665 Mln From $610 - $660 Mln
8/3/2021 8:06:02 AM Alnylam Pharma Q2 Non-GAAP Net Loss/shr Narrows To $1.30 From $1.67 Prior Year